Actively Recruiting
Preoperative Stereotactic Radiotherapy for Treatment of Spinal Metastases
Led by University Medical Center Goettingen · Updated on 2025-08-22
20
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research evaluates the use of preoperative hypofractionated Stereotactic Body Radiotherapy (SBRT) for patients undergoing surgery to treat spinal metastases, which are tumors that have spread to the spine from solid cancers. The study aims to determine if SBRT before surgery can control tumor growth at the affected spinal segments and improve postoperative outcomes such as pain, function, and quality of life. Participants will receive hypofractionated SBRT delivered in 1 to 3 sessions within one week after consenting, planned using MRI combined with CT scans and performed according to established institutional and ESTRO guidelines. Surgical treatment, which may include spinal canal decompression and/or stabilization with instrumentation, will occur within 10 days following consent, tailored to the patient's clinical needs. Throughout the study, participants will undergo MRI and CT scans before surgery, shortly after, and at 3 and 6 months post-surgery to assess tumor size and local control. They will complete questionnaires evaluating pain intensity, physical limitations, and overall quality of life. Researchers will also monitor wound healing, functional status, and any surgical instrumentation issues up to 6 months after treatment. The involvement includes preoperative and multiple follow-up assessments to measure safety and effectiveness outcomes over time.
CONDITIONS
Brief Title
Preoperative Stereotactic Radiotherapy for Treatment of Spinal Metastases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Indication for surgical treatment of a spinal tumor
- Age 18 years or older
- Estimated survival longer than 6 months
- Ability to understand the study and decide to participate
You will not qualify if you...
- Age younger than 18 years
- Motor deficit or loss of bladder and bowel control requiring emergency surgical decompression
- Tumor extent unsuitable for hypofractionated SBRT in 1-3 fractions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 1 week
Participants receive hypofractionated SBRT to spinal metastases in 1 to 3 fractions within one week after informed consent, planned using MRI and CT imaging.
1 to 3 visits (in-person)
Duration - Typically within 10 days after informed consent
Surgical intervention is performed following SBRT, including decompression of the spinal canal and/or dorsal instrumentation depending on clinical indication.
1 hospitalization visit (in-person)
Duration - Up to 6 months after treatment
Participants are monitored for pain relief, wound healing complications, and tumor control at discharge and at 3 and 6 months after treatment.
3 visits (in-person) at discharge, 3 months, and 6 months after treatment
Trial Site Locations
Total: 1 location
1
University Medical Center Goettingen
Göttingen, Germany, 37073
Actively Recruiting
Research Team
C
Carla Marie Zwerenz, Dr. med.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here